A Phase 2/3 interventional study of Vortioxetine and Treatment as Usual in Cannabis Use Disorder, Depressive State and Anxiety State, sponsored by The University of Hong Kong. Completed at 1 site in Hong Kong. Open to participants aged 16 Years to 50 Years. Per ClinicalTrials.gov, last updated 2023-07-05.
Sponsored by The University of Hong Kong · Phase 2/3, Interventional, and Treatment
Among 30 studies testing vortioxetine in Depression — 3 open to participants now, 3 under way, none of them phase 3. Vortioxetine · Depression.
Among the 30 studies testing vortioxetine in Depression, this one is the 23rd largest by enrollment, is the only one that started in 2018, is one of 2 in phase 2/3, and was the 22nd registered.
8,582 studies on the registry are indexed under Depression; 1,723 are open to participants now.
Browse Depression studies →3 of the 30 studies testing vortioxetine in Depression are open now, in 2 countries. Recruiting first, the newest first:
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 13–18
IRCCS San Raffaele Roma · Sites in Italy
Ages 30–80
Marianna Amboni
Ages 18+
By country, each count listing its studies:
Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 1,089 Depression studies recruiting now, 470 (43%) set no upper age limit and 519 (48%) stop at 75 or younger; 203 take children under 18; 311 take healthy volunteers.
This study: 16 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 16 · Phase 4 11
First in 2008; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 81 across 7,066 interventional studies indexed under Depression.
Median enrollment 223 across the 30 interventional studies. Of the 22 that completed or were terminated, 17 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 30 have an industry lead sponsor. The 10 most frequent:
The University of Hong Kong is the lead sponsor of 1,292 studies on the registry; 348 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
55 studies in Depression by The University of Hong Kong: 16 open now, 17 under way, none of them phase 3. Of 25 finished, 1 (4%) have results posted.
Among the 55 studies in Depression by The University of Hong Kong, this one is the 49th largest by enrollment of the 52 interventional ones that give a count, is one of 2 that started in 2018, is one of 2 in phase 2/3, and was the 14th registered.
The University of Hong Kong’s Depression studies by the year they started, since 2007.
2 of the studies testing vortioxetine in Depression that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06805266Marianna AmboniVortioxetine for Depressive Symptoms and Freezing of Gait in Parkinson Disease | 2026-12 |
| NCT05814640First Affiliated Hospital of Chongqing Medical UniversitySequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 30 studies testing vortioxetine in Depression, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among The University of Hong Kong’s 55 in Depression:
This tab as a report to print or save as PDF → With an account.
With the recent availability of vortioxetine, and the surging phenomenon of cannabis misuses amongst young abusers, it is a timely opportunity to conduct an early pharmacotherapy intervention study to offer an evidence-based strategy aiming to stop individuals with cannabis use disorders with depressive or anxiety symptoms, to develop into a more chronic disabling dependence or co-morbid state.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral: 5-20mg daily
Drug: Vortioxetine
Any medication or Rx other than vortixoetine
Other: Treatment as Usual
oral medication taken once daily
Any pharmacological or non-pharmacotherapy modalities other than use of vortioxetine
change in severity of Cannabis Use Disorder (CUD)
Change in severity of the cannabis use disorder for the 2 arms as defined by DSM-5
Time frame: 6 months
prevalence of Cannabis induced mood disorder
The prevalence of the cannabis induced disorder in both arms
Time frame: 6 months
Change in Hamilton anxiety (HAM-A) rating scale
To assess the change of anxiety severity of the two treatment arms using HAM-A for both treatment arms with cut-off of defining anxiety \>=14
Time frame: 6 months
Change in Hamilton depression (HAM-D) rating scale
To assess the change of depression severity of the two treatment arms using HAM-D for both treatment arms with cut-off of defining depression \>=8
Time frame: 6 months
Change in cognitive outcome
To assess the change in cognitive outcome using Frontal Assessment Battery in the two treatment arms
Time frame: 6 months
Ran from Jul 2018 to primary completion in Feb 2023, 55 months.
Of 30 non-industry phase 2/3 interventional studies under Depression, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 56. This study's 55 months is above that.
Counting every sponsor, half of 32 studies reached it within 40 months; a quarter within 27 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine